focus -WSS

focus

author：comprehensive 2025-09-30 21:22:31 - browse：89941

A hand in pink glove holds a blue rack that contains three tubes of blood samples — first opinion coverage from STAT — Joe Raedle/Getty Images

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the sites running the trials and the patients participating in them. Everyone from trial sponsors to the Food and Drug Administration has been quick to promise simpler processes, less hassle, and better experiences for everyone involved.

But look closer, and you’ll see that these grand promises often fall apart when sponsors implement complicated plans for collecting blood, tissue and other biospecimens and impossible processes for managing those samples. Behind all the talk and regulatory guidance, there’s a reluctance to change how these essential elements of clinical trial execution are handled, putting the very ideals that sponsors are trying to uphold at risk.

The concept of site and patient centricity frequently gets reduced to addressing only superficial gestures, such as committing to promptly paying sites for their work or using tablets for conducting patient surveys. But the essence of centricity extends far beyond these surface-level measures. It lies in addressing the unseen and unmentioned complexities of clinical trials and providing real solutions that focus on truly prioritizing the needs of trial sites and participants.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

WSS

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Global cancer cases to surge 77% by 2050, WHO report says

AstraZeneca stays mum on Medicare drug pricing negotiations

Global cancer cases to surge 77% by 2050, WHO report says

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Gene therapy for Afghan refugees’ infant will be fully covered

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Duchenne breakthrough therapy leaves behind pioneering families

What’s missing from the debate over nursing home staff minimums

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New documents shed light on MD Anderson Cancer Institute feud

Apple is now the first public company to be valued at $3 trillion

A new nitrogen execution bill also undermines medical licensing

The cancer drug shortage isn’t new — and neither are the solutions

Medicare inequities exacerbate Puerto Rico’s health disparities

Activists slam private health insurers over coverage restrictions

Padmanee Sharma of MD Anderson at center of lawsuit over credit

focus

Dario to buy mental health app maker Twill in cash and stock deal

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Surgery pushed Ben Carson to fame

A solution to the after

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Readout LOUD: Venture capital, Gilead, and more M&A

hotspot

entertainment

entertainment

focus